TheraRadar
← Back
Data updated: Jun 28, 2026

QILU

Generics
OncologyCardiovascularInfectious Disease Execution: Needs Improvement

QILU is a generic drug manufacturer focused on Oncology, Cardiovascular, Infectious Disease.

2016
Since
17
Drugs
-
Trials
0
New Drugs (2yr)

QILU at a Glance

  • Growing R&D activity with 19 trials in last 2 years
  • Fast trial execution (31 months median completion)

QILU's Key Drugs

QILU's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

QILU's Recent FDA Approvals

New NDA/BLA approvals for QILU over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

QILU's Therapeutic Areas

QILU's approved drugs and pipeline span 5 therapeutic areas, led by Oncology and Cardiovascular. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Oncology 65%
4 drugs Phase 3: 18 Phase 2: 11 Phase 1: 29
Cardiovascular 11%
1 drugs Phase 3: 3 Phase 2: 2 Phase 1: 3
Infectious Disease 10%
1 drugs Phase 3: 3 Phase 2: 1 Phase 1: 2
Immunology 8%
1 drugs Phase 3: 2 Phase 2: 1 Phase 1: 2
Dermatology 7%
0 drugs Phase 3: 2 Phase 2: 2 Phase 1: 3

QILU Pipeline Snapshot

QILU has 84 active clinical programs from ClinicalTrials.gov — 28 Phase 3, 17 Phase 2 and 39 Phase 1.

28
Phase 3
17
Phase 2
39
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • Top drug revenue breakdown
  • • Drug-level revenue analysis

Trial Catalysts

  • • Oncology pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 0/0 completed
  • • Speed: 31 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges